Ascendis Pharma Scores FDA Approval for Yuviwel – Weekly Injection to Boost Growth in Achondroplasia
FDA approves Ascendis Pharma's Yuviwel, the first once-weekly injection to boost growth in children 2+ with achondroplasia. Launch expected Q2 2026.
FDA approves Ascendis Pharma's Yuviwel, the first once-weekly injection to boost growth in children 2+ with achondroplasia. Launch expected Q2 2026.
Ascendis Pharma shares rose 5% after new takeover speculation involving European pharmaceutical companies, according to market chatter.